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Abstract 
Background: Opioid-related morbidity and mortality is a serious public health issue in the United 
States.  Prescription Drug Monitoring Program (PDMP) review prior to prescribing opioids has 
consistently been recommended as best practices for risk mitigation, however, access/utilization 
of this monitoring program remains low.   
Methods: This quality improvement (QI) project for improved PDMP utilization employed a pre-
post survey design in a random sample of Advanced Practice Registered Nurses in Arizona.  
Quantitative measures included online surveys with close-ended responses to salient items from 
the review of literature and best practices.  A follow-up survey was requested of the participants 
who provided their email address one month following initial survey/best practice review. 
Results:  Forty-six APRNs responded to the preliminary survey.  Of the initial respondents, 22 
completed the post-intervention survey one month after the QI activity.  APRNs reported 
improved compliance with best practice recommendations including initial PDMP review prior 
to prescribing opioid medication for non-cancer, non-terminal pain, reviewing morphine 
milligram equivalents (MMEs) of prior prescriptions, < 3 month PDMP review for patients 
receiving chronic opioid medication, APRN addressing concerning PDMP review results, and 
maintaining an opioid dosage < 50 MMEs.   
Conclusions: Targeted educational awareness for APRNs can improve utilization of PDMPs and 
support increased adherence to safe, opioid prescribing best practices.   
Keywords: Opioid prescribing, prescription drug monitoring programs 
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Mitigating Prescription Opioid Risk:  Prescription Drug Monitoring Programs 
Introduction 
In the next hour, eight Americans will die from an opioid overdose.  Of that number, four 
will be from prescription opioids (Centers for Disease Control and Prevention [CDC], 2017).  
Prescription opioid deaths are preventable. One method of risk mitigation involves utilizing 
Prescription Drug Monitoring Programs (PDMPs).  PDMPs gather, observe, and analyze 
electronically transmitted, patient-specific, controlled substances data submitted by pharmacies 
and dispensing practitioners.  Reviewing the PDMP has consistently been recommended as best 
practice for reducing prescription opioid morbidity and mortality risk (Chou et al., 2014; Dowell, 
Haegerich, & Chou, 2016).  However, utilization rates remain low.  For example, findings reveal 
only 22% of Arizona prescribers were registered with the Arizona Controlled Substances 
Prescription Monitoring Program (AZCSPMP) (Dodge, 2017).  Actual utilization is likely even 
lower.  Failure to check the PDMP can result in the patient receiving a lethal medication 
combination.   
Background 
The United States (U.S.) accounts for approximately 5% of the world’s population but 
consumes 80% of the global opioid supply (International Narcotics Control Board, 2009).  
Opioid prescriptions in the U.S. have increased since 1999 with a concurrent increase in opiate-
related deaths (CDC, 2011; Hedegaard, Warner, & Miniño, 2017) and are responsible for almost 
half of overdose deaths (Rudd, Seth, David, & Scholl, 2016).  Annual U.S. overdose deaths now 
surpass the number from auto accidents (U.S. Department of Health & Human Services [DHHS], 
2015).   
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Significant historical events contributed to opioid pain reliever (OPR) popularity.  
Pharmaceutical company, Purdue Pharma, released OxyContin to the market in 1995.  An 
aggressive marketing campaign included financial grants encouraging the use of OPRs in 
chronic, non-cancer pain. The American Pain Society began the “pain is the fifth vital sign” 
campaign which the Joint Commission also adopted.  Pain was given the same clinical 
significance as objective findings such as temperature, pulse, respiration rate, and blood pressure.  
Despite lack of evidence for long-term efficacy, OPR prescriptions continue to rise (Hedegaard, 
et al., 2017; Kolodny et al., 2015).   
In response to the surge in opioid-related morbidity and mortality, the CDC (2017) issued 
a state-wide “call to action.”  Accordingly, on June 5th, 2017, Arizona Governor Douglas Ducey 
declared a public health emergency (State of Arizona, 2016) and created a task force to address 
this epidemic (Arizona Department of Health Services [ADHS], 2017a).  The ensuing Opioid 
Overdose Epidemic Response Report provided recommendations consistent with best practice 
guidelines (ADHS, 2017b), including a mandate requiring that prior to prescribing a Schedule II, 
III or IV opioid analgesic or benzodiazepine, a provider must acquire a PDMP patient utilization 
report for the preceding 12 months (Amending Sections 36-2606 and 36-2608, 2016).   
The CDC has provided twelve recommendations for long-term prescription opioid use in 
adults ages 18 and older with chronic, non-cancer, non-terminal pain.  These include three main 
categories.  One category is targeted at assessing risk and addressing opioid use harms (Dowell, 
et al., 2016).  Risk mitigation strategies correspond with the Institute of Medicine [IOM] (2001) 
dimensions of quality, specifically safe and effective care.  Improved safety is reflected by 
decreased morbidity and mortality from an adverse event or harm.  Several studies have 
supported introduction of a state PDMP and reductions in strength and/or quantity of opioid 
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prescriptions (Bao et al., 2016; Deyo et al., 2018; Wen, Schackman, Aden, & Bao, 2017; 
Yarbrough, 2017) as well as a reduction in opioid-related deaths (Patrick, Fry, Jones, & Buntin, 
2016) and opioid abuse (Reifler et al., 2012).  National and local publicity highlighting the 
opioid crisis is a “hot button” topic reinforcing best practice implementation.  While providers 
are invested in safe care, barriers to best practice implementation exist.  Provider practice varies, 
with some providers monitoring the PDMP while others do not.   
Problem Statement 
The risk of overdose/death among Arizona adults 18 years of age and older prescribed 
long-term opioids for non-cancer, non-terminal pain is indicated by morbidity and mortality 
statistics and results from deficits in risk identification including prescriber utilization of the state 
PDMP.  A Quality Improvement (QI) project which promotes improvement of AZCSPMP 
utilization is suggested. 
Organizational “Gap” Analysis of Project Site 
The Agency for Health Care Research and Quality (AHRQ) supports quality and safety 
as it relates to prescribing long-term opioids for chronic pain (Chou et al., 2014).   The gap 
relates to the Arizona state mandate requiring providers check the AZCSPMP prior to 
prescribing controlled substances and at minimum specific intervals thereafter.  Despite 
legislative mandate, prescriber registration and utilization are low.   
Review of the Literature 
A database search of PubMed and The Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) was performed for articles dated January 1, 2013 to present.  Medical 
Subject Headings (MeSH) terms searched in both databases were prescription drug monitoring 
programs AND utilization and prescription drug monitoring programs AND barriers.  One 
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hundred fifty-one articles were retrieved from the search, including 91 articles from PubMed and 
60 from CINAHL.  The database search on PDMPs and utilization yielded 66 articles from 
PubMed and 44 from CINAHL.  PDMPs and barriers generated 25 and 16 articles from PubMed 
and CINAHL, respectively.  Publications were reviewed for inclusion.  Of the articles on PDMPs 
and utilization, 50 were excluded from the PubMed results and 36 from CINAHL.  Twelve 
articles were excluded from the PubMed results and nine from the CINAHL search on PDMPS 
and barriers. Inclusion criteria for the review was full-text, peer-reviewed, English language 
articles.  Excluded articles were four editorials, four best practices/guidelines, 11 focusing on 
pharmacists, 49 specific to patient level date, nine relating to PDMP policy, and five educational 
articles.  Additional excluded articles consisted of one case study, 15 irrelevant articles, two poor 
quality studies, and 16 policy reviews.  Also, one article written in Spanish and three articles 
which were not peer-reviewed were omitted.  Poor quality studies lacked adequate sample size, 
response rate, and/or were poorly designed.  Irrelevant articles either focused on an unrelated 
topic or opioid dispensing.  Lastly, 27 duplicate articles were excluded.  Review of article 
reference lists identified two additional articles for inclusion.  Six articles remained for review 
and synthesis.    
The six selected studies on PDMPs and opioid prescribing practices included one 
retrospective cohort study, one systematic review of case-control studies, one cross-sectional 
random sample survey, two cross-sectional non-randomized surveys, and one qualitative 
interview study.  The strength of recommendations and quality of the evidence was evaluated 
utilizing The Johns Hopkins Nursing Evidence-based Practice Rating Scale. Based upon 
scientific study design, strength of evidence is rated from a high of Level I to a low of Level V.  
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The quality of evidence represents the level of expertise evident and is rated high, medium, or 
low (Newhouse, Dearholt, Poe, Pugh, & White, 2005).   
PDMP Utilization 
PDMP utilization varies.  A frequent theme found prescribers rely heavily on their 
subjective impression of a patient when determining if PDMP review is indicated (Leichtling et 
al., 2016; Lin et al., 2018; Smith et al., 2015; Young et al., 2017).  Leichtling et al., (2017) 
evaluated a purposive sample of PDMP utilization.  Short-term prescribers i.e., those working in 
acute care facilities, reported inconsistent use of the PDMP.  Long-term prescribers, were more 
likely to check the PDMP for new patients and at spaced intervals for long-term patients.  
Strength of evidence:  Level III, Quality Level medium (Newhouse, et al., 2005).  However, 
physicians working in a managed care organization were less likely to utilize PDMP (Lin et al., 
2018).  Strength of evidence:  Level III, Quality Level medium (Newhouse et al., 2005).  
Pomerleau et al. (2016) found a mere 8% (n = 18) of surveyed emergency department (ED) 
prescribers check the PDMP with each patient.  Strength of evidence:  Level III, Quality Level 
medium (Newhouse et al., 2005).   
PDMP use was evaluated in a survey of physicians practicing in primary care, pain 
medicine and emergency medicine (Lin et al., 2017).  Participants utilizing the PDMP reported it 
was very easy (33%, n = 82) or somewhat easy (47%, n = 114) to use. Strength of evidence:  
Level II, Quality Level medium (Newhouse et al., 2005).  Other studies suggest significant 
barriers. 
PDMP Barriers 
Provider perception and satisfaction with the PDMP can affect utilization.  PDMP 
utilization and perception was evaluated by Young, Tyndall, and Cottler (2017).  Survey results 
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suggested barriers including difficulties in initial access, frequent password renewal, and timing 
out requiring re-entry of username/password. Strength of evidence:  Level III, Quality Level low 
(Newhouse et al., 2005).  Lin et al. (2017) also found 20% of respondents reported access issues.  
Similarly, Smith et al. (2015) found barriers including lack of awareness as well as access and 
time constraints.  Strength of evidence:  Level III, Quality Level medium (Newhouse et al., 
2005).   A survey of 515 emergency department (ED) providers revealed only 59% of 
respondents was registered with their PDMP. Fifty-three percent reported consulting the PDMP 
at least once a shift.  Sixty-three percent reported being satisfied (47%) or very satisfied (16%) 
with the state PDMP (Pomerleau et al., 2016).  
Several limitations are noted.  Self-report and retrospective information can impact 
reliability and validity of findings.  The lack of randomized clinical trials reduces data quality.  
Additionally, use of local/state-specific and non-randomized samples limit generalizability of 
data (Gravetter & Forzano, 2016).   
Utilization of the PDMP varies; lack of sanctions for non-compliance with state PDMP 
requirements may play a role in the findings. Subjective impression as criteria for PDMP 
utilization was supported by four studies (Leichtling et al., 2016; Lin et al., 2018; Smith et al., 
2015; Young et al., 2017).  While some individuals with substance use disorders have some 
similar physical characteristics, not all individuals look the same. Objective data is necessary to 
reduce the risk of targeting certain individuals and missing serious substance abuse in others. 
Lack of standardized state PDMP guidelines and enforcement of state mandates may limit data 
utility.   Despite governmental mandates, there is no standardized use of the PDMP.  Information 
on ease of access is conflicting.  Some prescribers report logistical interference. This could 
reflect user skill, time constraints, or individual provider decision.   
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Provider compliance with risk mitigation strategies supports best practices and IOM 
(2001) quality domains.  A QI project to support/improve PDMP utilization and PDMP access 
was indicated.  The goal was decreased morbidity and mortality by reducing high-risk opioid 
prescribing for patients with non-terminal, non-cancer pain.   
Evidence Based Practice: Verification of Chosen Option 
Reviewing the PDMP is recommended as best practice when prescribing long-term 
opioids (Chou et al., 2014; Dowell, et al., 2016).  Risk assessment and mitigation strategies, 
including reviewing the PDMP, are recommended to reduce the risk of unintentional 
overdose/death.   Providers may alter their treatment plan after reviewing information from the 
PDMP by reducing the quantity, strength, or duration of opioids prescribed.  
Theoretical Framework/Evidence Based Practice Model 
Fishbein and Ajzen’s (2010) Theory of Reasoned Action and Planned Behavior (most 
recently referred to as The Reasoned Action Approach) (Appendix A) is a theoretical framework 
developed to explore ways of predicting behaviors and outcomes.  They propose attitudes and 
perceived “norms” have an effect on behavior, that behavior is a function of behavioral 
intentions and perceived behavioral control (Fishbein & Ajzen, 2010).  For example, emergent 
governmental interventions and recent policy changes may be associated with an attitude change 
about opioid prescribing “norms.”  Clinicians' attitude toward the mandate and utility of the 
program affect use.  If prescribers perceive checking the PDMP as the new “norm,” there is 
increased probability providers will change their perspective on prescribing long-term opioids.  
The outcome measure was the behavior, in this case, PDMP review.  
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Goals, Objectives and Expected Outcomes 
Goals for the Capstone project included identifying facilitators and barriers of PDMP 
utilization and increasing APRN knowledge about PDMP utilization when prescribing long-term 
opioids for chronic pain.  
The objectives for this DNP project were to evaluate facilitating factors and barriers to 
utilization of the AZCSPMP and provide an online video review for PDMP best practices when 
prescribing opioid medication for non-cancer, non-terminal pain. 
The main outcome was improved utilization of the Arizona PDMP.  Utilization was 
defined as initial PDMP review prior to prescribing opioid medication for non-cancer, non-
terminal pain, reviewing morphine milligram equivalents (MMEs) of prior prescriptions, <3-
month PDMP review for patients receiving chronic opioid medication, APRN addressing 
concerning PDMP review results, and maintaining an opioid dosage < 50 MMEs.  It was 
anticipated that a QI video reviewing best practices would result in improved utilization of the 
AZCSPMP. 
The target for the outcome indicators was 30 percent compliance for all at baseline and 
60 percent at one month post initial survey/QI activity.  The target benchmark, an external 
benchmark, was set relative to the current state PDMP utilization rates for all prescribing 
providers prior to the surveys and QI presentation.  
Methods 
The proposed QI project utilized a random sample of Arizona advanced practice 
registered nurses (APRNs).  The sampling frame was entered into the Excel sheet.  
Randomization occurred using the “= RANDBETWEEN()” function.  A pre-/post-survey design 
was utilized.  Quantitative measures included online surveys with close-ended responses to 
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salient items from the review of literature and best practices.  The QI intervention, a risk 
mitigation video reviewing evidence-based practices for prescribing opioids, as well as 
requirements of the Arizona mandate, was presented to APRNs immediately following 
participants’ completion of the preliminary survey.  A follow-up survey was requested of the 
participants who provided their email address one month after initial survey/best practice review. 
Project Site  
An Arizona behavioral health organization provided clinical support for the Capstone 
QI project.  The business has a 31-year history of providing comprehensive, medically-integrated 
behavioral health programs.  They provide substance abuse treatment including detoxification, 
residential, and medication-assisted treatment.  Additionally, the organization provides integrated 
care treatment for co-morbid medical conditions including prevention, education, and treatment 
services using nationally recognized treatment models.  Services are provided at multiple sites 
throughout Arizona.   
The DNP student, as project director, provided a summary of findings to administrative 
members at project competition.  This will assist administration with future QI initiatives for 
provider prescribing. The findings will be particularly salient for ongoing QI efforts on safe 
prescribing practices including treatment of anxiety and substance use disorders as well as 
integrated health care.  
The project took place via online survey.  Required resources included APRN addresses, 
mailing materials, online survey site, online QI activity, and follow-up capacity.  The main 
barrier was the means available for contacting APRNs licensed to practice in Arizona.  By 
policy, the Arizona Board of Nursing will only release mailing addresses of licensed nurses, not 
email addresses (Arizona State Board of Nursing, 2018).  The project director requested the 
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mailing list.  Email communication with Kathy Malloch, PhD, MBA, RN, FAAN, Associate 
Director/Education and Evidence Based Regulation at Arizona State Board of Nursing confirmed 
approved use of the requested APRN list for the QI project (Appendix B).   The acquired list 
included the names of 8817 APRNs with active Arizona licenses.  The cost of mailing to all 
Arizona APRNs was cost prohibitive, therefore a random sample of 1700 was selected.  Other 
potential resources for email addresses included the Arizona Board of Pharmacy who manages 
the AZCSPMP and the American Academy of Nurse Practitioners.  The DNP student sent email 
communications to  these two potential sources inquiring on the availability of an email list of 
APRNs without success.    
Population 
Inclusion criteria were APRNs with active Drug Enforcement Administration (DEA) 
certificates and prescribing privileges within the state of Arizona completing pre- and post-
survey and QI activity.  Additional inclusion criteria consisted of APRNs who prescribe opioids 
for non-cancer, non-terminal pain in the state of Arizona from August 2018 through February 
2019.  Individuals falling outside of the above noted criteria were excluded. 
 The DNP student, as project director, was responsible for all phases of project 
development, implementation, data collection, data analysis, and evaluation. The implementation 
plan/procedures contained the following steps:  proposal write-up and approval, obtaining 
mailing list of APRNs practicing in Arizona, creating and ordering postcards, mailing 
postcards/email requesting participation.  A copy of the postcard content is included in Appendix 
C.  The next steps were developing an online survey by adapting a previously developed PDMP 
survey, posting the survey on Survey Monkey, creating and including a link to the QI activity at 
the end of the first survey, followed by requesting participants complete a follow-up survey one 
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month after QI activity.  The last steps included collecting, cleaning, and analyzing the data and 
final write-up.   
The goal sample size was determined utilizing an online calculator at SurveyMonkey.  
The total population size was 8819.  With a standard confidence interval of .80 and a margin of 
error of 0.05, a sample of at least 161 was required.  The anticipated response rate for an external 
mail survey is 10% (Gravetter & Forzano, 2016).  To obtain the minimum sample size, at least 
1610 invitations needed to be mailed; however, 1700 was the number of invitations mailed.  
Measurement Instruments 
The outcome variable was PDMP utilization via best practice behaviors and requirements 
of the Arizona mandate.  Coinciding with the theoretical framework, it was posited that attitude, 
outcome expectancies, perceived norms, perceived barriers/control factors, and behavior 
intention would influence PDMP utilization. Proposed mediating factors were attitude of PDMP 
usefulness, beliefs concerning prescription drug abuse, beliefs regarding peers’ utilization of the 
PDMP, perceived social and professional norms, perceived ethical obligation to use the 
AZCSPMP, and perceived confidence with or barriers to use of the PDMP.  Demographic and 
practice data were obtained from the survey.  A letter requesting permission to use the 23-item 
survey created by Pugliese, Wintemute, and Henry (2018) was mailed to the lead author 
(Appendix D).  Email communication with the lead study author granting permission was 
received and is included in Appendix E.  The DNP student created adapted versions of the 
survey which included items on risk mitigation strategies/best practices and additional items 
reflecting normative behaviors of best practices/risk mitigation. The adapted pre-and post-
intervention surveys are presented in Appendices F and G.  The project included a 35-question 
pre-intervention survey, a best practice review video, and a 27-question post-survey.   
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Data Collection Procedures  
 Data collection for the project entailed several steps.  A preliminary survey was made 
available on SurveyMonkey.  Presentation of PDMP utilization best practices to APRNs 
occurred as a web link at the end of the first survey.  The post-survey was administered to 
participants one month after the initial survey/online QI video presentation by the DNP project 
director.  A follow-up email address was requested in the initial survey to allow for follow-up 
communication.  Data cleaning and analysis followed.    
Ethical Considerations/Protection of Human Subjects 
The University of Massachusetts, Amherst (UMASS) IRB approval was obtained prior to 
initiating the DNP project and was completed in accordance with UMASS Amherst guidelines 
(Moran, Burson, & Conrad, 2014).  The official IRB Determination Form was submitted after 
the proposal was approved. Care, in accordance with best practices was expected to improve, 
therefore risk was minimized, and benefit was anticipated.  In order to protect the confidentiality 
of human subjects in the QI project, research and IRB review procedure complied with 45 C.F.R. 
§ 46 (Protection of Human Subjects, 2009).  Safeguards were utilized to assure favorable risk-
benefit ratio, respect for participants, informed consent, and independent review. The proposal 
involved pre-/post-survey with a QI activity for APRNs.  No patient data was collected.   
Respect for participants included protecting individually identifiable data elements, 
following recommended procedures for data storage and linking for information retrieval.  The 
DNP project director had sole access to this information which was in a double-locked location.  
Protected health information (PHI) was not utilized for any part of the project.   
Participant information for this project included: name, city/town, and state which was 
only utilized for the initial mailing. Race/ethnicity, clinical specialty, and email address were the 
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only participant information collected for the preliminary and post-intervention surveys.  This 
method assured participants’ anonymity was maintained.  Upon project completion, data was 
destroyed according to the institutional requirements (Moran, et al., 2014).   The Arizona Board 
of Nursing and the clinical site expressed support for the QI project and did not require IRB 
approval.   
Results 
Forty-six APRNs (n = 46) responded to the preliminary survey containing quantitative 
questions.  The pre-intervention survey included two preliminary inclusion questions on 
possession of Arizona prescriptive privileges and Federal DEA certificate.  One survey was 
excluded for lack of a DEA certificate, as that individual could not prescribe Schedule II opioids.  
Of the remaining 45 respondents, 22 completed the post-intervention survey.  Paired data was 
available on 8 participants.  The timeline for the project spanned from September 2018-April 
2019.  
Data Analysis 
Analyses were performed on aggregate, quantitative data.  An Excel sheet of survey 
responses was retained, compiled, and analyzed.  Data was scored using IBM’s Statistical 
Package for the Social Sciences (SPSS Statistics for Windows, Version 22.0). Data analysis was 
accomplished with basic descriptive statistics (frequencies and means/medians) for the 
structured-response items as well as demographic data.  Relationships between survey items 
were analyzed with the nonparametric Spearman’s rank-order correlation.  This methodology 
was utilized due to the dependent variable being measured on an ordinal level as well as being 
highly skewed (Polit, 2010).   
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Independent variables included demographic data as well as questions reflecting concepts 
from Fishbein and Ajzen’s (2010) Theory of Reasoned Action and Planned Behavior.  
Theoretical framework concepts included categories of normative beliefs, attitude, outcome 
expectancies, and behavior intention. 
 Dependent variables were operationalized utilizing five questions specific to opioid 
prescribing best practices.  Responses were at the ordinal level of measurement on five and six-
point Likert scales.  Responses to the five questions reflecting best practices were transformed to 
dichotomous responses.  These five variables were recoded to dummy variables for data analysis 
with values of 0 (no) and 1 (yes).  Only one potential response from each question was coded 
affirmatively, reflecting responses every day and always.  Results of self-reported best practice 
behaviors are presented in Table 1.   
Table 1 
 
Self-reported Best Practice Behaviors 
 
Behavior 
 
Preliminary Survey (n = 45) 
 
Post-intervention Survey (n = 22) 
 
 
Check initial 12-month PDMP 
report prior to prescribing 
opioids. 
% (n) 
 
11.1% (5) 
% (n) 
 
31.8% (7) 
 
Review morphine milligram 
equivalents (MMEs) or prior 
prescriptions. 
 
11.1% (5) 
 
36.4% (8) 
 
Check the CSPMP > every 3 
months for patients receiving 
opioids. 
 
51.1% (23) 
 
59.1% (13) 
 
Document concerning PDMP 
results. 
 
 
57.8% (26) 
 
63.6% (14) 
Maintain an opioid dosage < 50 
MMEs per day. 
 
37.8% (17) 50.0% (11) 
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Findings suggest increased adherence to best practices across all five recommendations 
after online video review. APRNs reported 57.8% compliance with addressing concerning 
PDMP review results in the preliminary survey.  This increased to 63.6% post-best practice 
review, exceeding the 60% target set, and resulted in the objective for that indicator being met.   
Targets for the four other indicators were not met.  In the preliminary survey, 11.1% reported 
initial PDMP review prior to prescribing opioid medication for non-cancer, non-terminal pain 
while 31.8% of the post-intervention group reported completing the review.  Reviewing MMEs 
of prior prescriptions was reported in 11.1% and 36.4% pre- and post-intervention, respectively.  
Pre-intervention, 51.1% reported <3-month PDMP review for patients receiving opioids, while 
59.1% reported post-intervention adherence.  Lastly, maintaining an opioid dosage < 50 MMEs 
increased to 50.0% post-implementation from 37.8% reported at baseline.   
Demographic information presented in Table 2 was obtained for the preliminary survey 
sample (n = 45).   The sample was 88.9% female and 11.1% male. Race/ethnicity of participants 
included White (91.1%), Black (4.4%), and Asian (4.4%) with 4.4% Hispanic/Latino. Practice 
area responses were recoded from the original survey responses to family practice, specialty 
clinic, women’s health/midwifery/OBGYN, behavioral health/psychiatry, and urgent/emergency 
care/trauma. Recoding was completed based upon the large number of responses listed in the 
“other” category.   
Skewness indices revealed results of demographic data reflecting gender, race/ethnicity, 
Hispanic ancestry, and length of time as an APRN was highly skewed.  Survey results on length 
of time as an APRN revealed most study participants had less than five years of experience.  This 
violated the assumptions of a normal distribution and influenced data analysis methods (Polit, 
2010).   
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Table 2 
 
Demographic and Clinical Characteristics of the Sample Retained for Analysis. 
 
Characteristic 
 
 
Pre-best practice review (n=45) 
Gender % (n) 
Male 
Female 
Age % (n) 
25 to 34 
35 to 44 
45 to 54 
55 to 64 
65 to 74 
Mean years in practice (n) 
Length of time utilizing CSPMP % (n) 
Less than 3 months 
3-6 months 
6-12 months 
More than 1 year 
Race/ethnicity % (n) 
White 
Black 
American/Alaskan Native 
Asian 
Native Hawaiian/Pacific Islander 
Other 
Hispanic or Latino % (n) 
Yes 
No 
Specialty % (n) 
Family practice 
Specialty clinic 
Women’s health/ Midwifery/OBGYN 
Behavioral health/psychiatry 
Urgent/emergency care/trauma 
 
 
11.1% (5) 
88.9% (40) 
 
13.3% (6) 
35.6% (16) 
26.7% (12) 
22.2% (10) 
2.2% (1) 
8.2 years 
 
2.2% (1) 
11.1% (5) 
11.1% (5) 
75.6% (34) 
 
91.1% (41) 
4.4% (2) 
0.0% (0) 
4.4% (2) 
0.0% (0) 
0.0% (0) 
 
4.4% (2) 
95.6% (43) 
 
28.9% (13) 
28.9% (13) 
11.1% (5) 
11.1% (5) 
20.0% (9) 
 
Normative beliefs were analyzed by questions on professional and moral obligation with 
responses on a five-point Likert scale and were operationalized by asking what percentage of 
peers the respondent felt should and actually did check the CSPMP at least weekly (Table 3).  
In the preliminary survey, 18.2% (n = 8) believed 91-100% of their colleagues utilized 
AZCSPMP weekly, while 71.1% (n = 32) thought 91-100% of their colleagues should utilize the 
AZCSPMP weekly. Interestingly, in the post-survey, the number of APRNs who believed 91-
100% of their colleagues used the PMP weekly dropped to 4.5% (n = 1), while there was an 
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increase in the number (72.7%, n = 16) who believed 91-100% ought to use the PMP at least 
weekly.  
Table 3 
Quantitative Survey Data by Theoretical Framework Concept of Normative Beliefs 
 
Question 
 
Response 
 
Preliminary (n = 45) 
% (n) 
 
Post-Intervention (n = 22) 
% (n) 
 
What percentage of your colleagues do 
you think uses the CSPMP at least 
weekly? 
 
None 
1-10% 
11-20% 
21-30% 
31-40% 
41-50% 
51-60% 
61-70% 
71-80% 
81-90% 
91-100% 
 
6.8% (3) 
9.1% (4) 
0.0% (0) 
4.5% (2) 
2.3% (1) 
13.6% (6) 
18.2% (8) 
11.4% (5) 
9.1% (4) 
6.8% (3) 
18.2% (8) 
 
0.0% (0) 
9.1% (2) 
4.5% (1) 
9.1% (2) 
4.5%  (1) 
9.1% (2) 
9.1% (2) 
4.5% (1) 
27.3% (6) 
18.2% (4) 
4.5% (1) 
 
What percentage of your colleagues do 
you feel ought to be using the CSPMP at 
least weekly?  
None 
1-10% 
11-20% 
21-30% 
31-40% 
41-50% 
51-60% 
61-70% 
71-80% 
81-90% 
91-100% 
0.0% (0) 
6.7% (3) 
2.2% (1) 
0.0% (0) 
0.0% (0) 
8.9% (4) 
2.2% (1) 
2.2% (1) 
2.2% (1) 
4.4% (2) 
71.1% (32) 
0.0% (0) 
4.5%  (1) 
0.0% (0) 
4.5%  (1) 
0.0% (0) 
0.0% (0) 
9.1% (2) 
0.0% (0) 
0.0% (0) 
9.1% (2) 
72.7% (16) 
 
I have a professional responsibility to 
check the CSPMP when prescribing/ 
dispensing controlled substances.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree  
0.0% (0) 
0.0% (0) 
2.2% (1) 
20.0% (9) 
77.8% (35) 
0.0% (0) 
0.0% (0) 
0.0% (0) 
22.7% (5) 
77.3% (17) 
 
Checking the CSPMP when prescribing/ 
dispensing controlled substances is the 
right thing to do.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
0.0% (0) 
0.0% (0) 
2.2% (1) 
17.8% (8) 
80.0% (36) 
 
0.0% (0) 
0.0% (0) 
4.5% (1) 
13.6% (3) 
81.8% (18) 
Using the CSPMP when prescribing/ 
dispensing controlled substances is 
considered standard of care.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
0.0% (0) 
6.7% (3) 
2.2% (1) 
24.4% (11) 
66.7% (3) 
0.0% (0) 
0.0% (0) 
9.1% (2) 
18.2% (4) 
72.7% (16) 
 
Prescribing/dispensing controlled 
substances without checking the CSPMP 
would be morally wrong.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
2.2% (1) 
24.4% (11) 
35.6% (16) 
22.2% (10) 
15.6% (7) 
0.0% (0) 
4.5% (1) 
45.5% (10) 
22.7% (5) 
27.3% (6) 
 
Checking the CSPMP when prescribing/ 
dispensing controlled substances is not a 
necessary part of my job. 
 
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
 
53.3% (24) 
35.6% (16) 
6.7% (3) 
2.2% (1) 
2.2% (1) 
 
50.0% (11) 
45.5% (10) 
0.0% (0) 
4.5% (1) 
0.0% (0) 
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Regarding professional obligation, after the best practice review, an increased percentage 
of providers (72.7%, n =16 versus 66.7%, n =30) reported using the CSPMP when prescribing/ 
dispensing controlled substances is considered standard of care.   
Moral obligation also appeared to improve post-intervention with 50.0% (n = 11) versus 
37.8% (n = 17) reporting they agreed or strongly agreed prescribing/dispensing controlled 
substances without checking the CSPMP would be morally wrong. 
Prescriber attitude regarding APRN concern of substance abuse statewide as well as 
within their respective practice community was evaluated utilizing a three-point Likert scale and 
is presented in Table 4.   Providers reported increased concern about substance abuse statewide 
(n = 29, 64.4%, ) versus in their practice community ( n = 27, 60.0%) in the preliminary survey.  
However, in the post-intervention survey concern was equal for the state and local community 
(59.1%, n = 13).  
Table 4 
Quantitative Survey Data by Theoretical Framework Concept of Attitude 
 
Question 
 
Response 
 
Preliminary (n = 45) 
% (n) 
 
Post-Intervention (n = 22) 
% (n) 
 
How concerned are you 
about prescription drug 
misuse and abuse among 
patients in Arizona? 
 
Not at all 
A moderate amount 
A great deal 
 
2.2% (1) 
33.3% (15) 
64.4% (29) 
 
0.0% (0) 
40.9% (9) 
59.1% (13) 
 
How concerned are you 
about prescription drug 
misuse and abuse among 
patients in the community 
where you practice? 
 
 
Not at all 
A moderate amount 
A great deal 
 
4.4% (2) 
35.6% (16) 
60.0% (27) 
 
4.5% (1) 
36.4% (8) 
59.1% (13) 
 
Outcome expectancies were garnered from survey questions on perceived PDMP utility 
(four-point Likert scale) and perceived PDMP barriers/control factors (five-point Likert scale).  
Provider perception of PDMP utility regarding building trust as well identifying patients who 
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obtain/fill multiple prescriptions and misuse controlled prescription medication were noteworthy.  
Understandably, 50.0% or fewer of providers reported the PDMP was very helpful for building 
trust both pre- and post-intervention.  Alternatively, most providers reported great utility in 
identifying patients who fill multiple controlled substance prescriptions and/or misuse 
prescription medication (Table 5). 
Table 5 
Quantitative Survey Data by Theoretical Framework Concept of Outcome Expectancies:  Utility 
 
Question 
 
Response 
 
Preliminary(n = 45) 
% (n) 
 
Post-Intervention(n = 22) 
% (n) 
 
How useful to you is the Arizona 
Controlled Substances Prescription 
Monitoring Program (CSPMP) for 
helping manage patients with pain?  
 
Not at all useful 
Not so useful 
Somewhat useful 
Very useful 
 
0.0% (0) 
4.4% (2) 
15.6% (7) 
80.0% (36) 
 
0.0% (0) 
4.5% (1) 
13.6% (3) 
81.8% (18) 
 
How useful to you is the CSPMP for 
helping build trust with patients?  
Not at all useful 
Not so useful 
Somewhat useful 
Very useful 
0.0% (0) 
13.3% (6) 
37.8% (17) 
48.9% (22) 
0.0% (0) 
9.1% (2) 
40.9% (9) 
50.0% (11) 
 
How useful to you is the CSPMP for 
informing decisions to 
prescribe/dispense controlled 
substances?  
Not at all useful 
Not so useful 
Somewhat useful 
Very useful 
2.2% (1) 
2.2% (1) 
17.8% (8) 
77.8% (35) 
 
0.0% (0) 
0.0% (0) 
22.7% (5) 
77.3% (17) 
How useful to you is the CSPMP for 
identifying patients filling 
prescriptions from multiple doctors 
and/or pharmacies?  
Not at all useful 
Not so useful 
Somewhat useful 
Very useful 
0.0% (0) 
0.0% (0) 
6.7% (3) 
93.3% (42) 
 
0.0% (0) 
0.0% (0) 
13.6% (3) 
86.4% (19) 
How useful to you is the CSPMP for 
identifying patients who misuse or 
abuse controlled prescription drugs?  
Not at all useful 
Not so useful 
Somewhat useful 
Very useful 
0.0% (0) 
2.2% (1) 
26.7% (12) 
71.1% (32) 
0.0% (0) 
0.0% (0) 
22.7% (5) 
77.3% (17) 
 
 
Barriers and control factors representing additional theoretical framework concepts of 
outcome expectancies are presented in Table 6.  Factors specific to perceived barriers and control 
included reviewing perceived PDMP utility, relevance, access, and ease of use.  After best 
practice review, 77.3% (n = 17) strongly agreed the AZCSPMP is helpful and 44.5% (n = 10) 
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reported it was easy to use in contrast to pre-intervention of 66.7% (n = 30) and 42.2% (n = 19), 
respectively. 
Table 6 
Quantitative Survey Data by Theoretical Framework Concept of Outcome Expectances:  
Barriers/Control Factors 
 
Question 
 
Response 
 
Preliminary(n = 45) 
% (n) 
 
 
Post-Intervention (n = 22) 
% (n) 
The CSPMP is helpful.  Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
2.2% (1) 
0.0% (0) 
2.2% (1) 
28.9% (13) 
66.7% (30) 
0.0% (0) 
0.0% (0) 
4.5% (1) 
18.2% (4) 
77.3% (17) 
 
The CSPMP is not relevant to 
my practice.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
57.8% (26) 
24.4% (11) 
6.7% (3) 
8.9% (4) 
2.2% (1) 
50.0% (11) 
40.9% (9) 
0.0% (0) 
0.0% (0) 
9.1% (2) 
 
The CSPMP is easy to use.  Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
0.0% (0) 
6.7% (3) 
11.1% (5) 
40.0% (18) 
42.2% (19) 
 
0.0% (0) 
4.5% (1) 
4.5% (1) 
45.5% (10) 
45.5% (10) 
I don’t know how to use the 
CSPMP.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
62.2% (28) 
28.9% (13) 
4.4% (2) 
4.4% (2) 
0.0% (0) 
68.2% (15) 
27.3% (6) 
0.0% (0) 
4.5% (1) 
0.0% (0) 
 
I have limited or no access to 
the CSPMP while I practice.  
Strongly disagree 
Disagree 
Neither disagree or agree 
Agree 
Strongly agree 
62.2% (28) 
28.9% (13) 
6.7% (3) 
2.2% (1) 
0.0% (0) 
63.6% (14) 
27.3% (6) 
4.5% (1) 
4.5% (1) 
0.0% (0) 
 
The CSPMP is checked by 
someone else in the office. 
 
Never 
Rarely 
Sometimes 
Usually 
Always 
 
44.4% (20) 
22.2% (10) 
17.8% (8) 
11.1% (5) 
4.4% (2) 
 
45.5% (10) 
13.6% (3) 
18.2% (4) 
13.6% (3) 
9.1% (2) 
 
  
Behavior intention appeared to increase post-QI intervention.  APRNs reporting being 
likely or extremely likely to utilize the CSPMP in the next 3 months improved from 91.2% in the 
preliminary survey to 95.5% post-intervention (Table 7).   
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Table 7 
Quantitative Survey Data by Theoretical Framework Concept of Behavior Intention 
 
Question 
 
 Response 
 
Preliminary(n = 45) 
% (n) 
 
Post-Intervention(n = 22) 
% (n) 
How likely are you to use 
the CSPMP at least once in 
the next three months? 
 
Extremely unlikely 
Unlikely 
Likely 
Extremely likely 
 
6.7% (3) 
2.2% (1) 
15.6% (7) 
75.6% (34) 
 
0.0% (0) 
4.5% (1) 
18.2% (4) 
77.3% (17) 
 
Findings did not support a relationship between practice area and best practice adherence 
(Table 8).  Study outcomes were not consistent with literature review findings of increased 
utilization in long-term prescribers.  Long-term prescribers were represented by the family 
practice category in this sample. 
Table 8 
Correlation between Practice Area and Best Practice Behaviors 
 
 
Check 12-month 
CSPMP prior to 
opioid rx. 
 
Review MMEs 
prior to opioid rx. 
 
 
Check CSPMP 
every 3 months 
  
Document 
concerning 
PDMP results 
 
Maintain opioid 
dosage <50 
MMEs per day 
 
Practice  area Correlation Coefficient -.075 -.180 -.137 .027 .085 
 
Sig. (2-tailed) .622 .238 .370 .860 .579 
N 45 45 45 45 45 
 
 
Table 9 
Correlation between Reported CSPMP Ease of Use and Best Practice Behaviors 
 
 
Check 12-month 
CSPMP prior to 
opioid rx. 
 
Review MMEs 
prior to opioid 
rx. 
 
 
Check CSPMP 
every 3 months 
  
Document 
concerning 
PDMP results 
 
Maintain opioid 
dosage <50 
MMEs per day 
 
CSPMP is easy to use Correlation Coefficient .376* .245 .414** .071 .064 
 
Sig. (2-tailed) .011 .105 .005 .645 .674 
N 45 45 45 45 45 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Consistent with prior studies, a relationship between reported ease of use and PDMP 
utilization was suggested (Table 9).  Ease of CSPMP use was positively correlated with checking 
the CSPMP prior to prescribing opioids for chronic, non-cancer, non-terminal pain (rs = .376, p < 
.05) and checking the CSPMP every three months during opioid treatment (rs = .414, p < .001).   
An additional question was added to the post-intervention survey reflecting literature 
review findings that suggested prescribers limit checking the PDMP based upon subjective 
interpretation. Responses to this question supported prior findings that subjective interpretation 
plays a large role in whether they will request an AZCSPMP report.  Fourteen out of twenty-two 
(63.7%) respondents affirmed utilizing this method of decision making when deciding if 
substance misuse was of concern. 
Accordingly, no significant relationship was found between best practice behaviors and 
checking CSPMP by subjective impression.  This suggests prescribers who relied on subjective 
impression have not followed best practice recommendations (Table 10). 
Table 10 
 
Correlation between Checking CSPMP by Subjective Impression and Best Practice Behaviors 
 
Check 12-
month 
CSPMP prior 
to opioid rx. 
 
Review 
MMEs prior 
to opioid rx. 
 
 
Check 
CSPMP every 
3 months 
  
Document 
concerning 
PDMP results 
 
Maintain 
opioid dosage 
<50 MMEs 
per day 
 
Check 12-
month 
CSPMP prior 
to opioid rx. 
 
Check CSPMP 
by subjective 
impression 
Correlation Coefficient 1.000 -.054 .091 .001 -.179 .347 
Sig. (2-tailed) . .811 .686 .998 .425 .114 
N 22 22 22 22 22 22 
 
Discussion 
This DNP project utilized QI through best practice review for prescribing opioids in 
patients with chronic non-cancer, non-terminal pain. Best practices included initial PDMP 
review prior to prescribing opioid medication for non-cancer, non-terminal pain, reviewing 
morphine milligram equivalents (MMEs) of prior prescriptions, <3- month PDMP review for 
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patients receiving chronic opioid medication, APRN addressing concerning PDMP review 
results, and maintaining an opioid dosage < 50 MMEs.  Findings suggest increased APRN 
adherence to opioid prescribing best practices after online QI review.  The target for the outcome 
indicators of 30 percent compliance for all set at baseline and 60 percent at one month post initial 
survey/QI activity was met for one indicator, but was not met for four indicators.  Findings from 
this project supported previous outcomes that self-reported ease of access improved PDMP 
utilization initial 12-month PDMP review prior to prescribing opioid medication and <3- month 
PDMP review for patients receiving chronic opioid medication.  However, results did not 
support previous data suggesting practice area was associated with PDMP utilization.   
Theoretical framework concepts evaluated in this project included normative beliefs, 
attitude, outcome expectancies, barriers and control factors, and behavior intention.  Findings 
suggest a change in normative beliefs specifically improved adherence to best practice 
recommendations as well as an increased percentage of respondents believing peers ought to be 
checking the PDMP.  This supports theoretical framework concepts of professional and moral 
obligation as well.  It is possible best practice review signified a new normative behavior, 
contributing to improved adherence.   
An unexpected finding was the dramatic increase in PDMP registration rates.  
Information available from 2017 revealed only 22% prescribers were registered with the 
AZCSPMP (Dodge, 2017).  The sample in this project reported 100% compliance with the state 
mandate for AZCSPMP registration.  This is certainly an encouraging finding and suggests the 
mandate is aiding APRN compliance with best practice recommendations. 
Cost-Benefit Analysis/Budget 
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It is estimated that the DNP project director provided 760 donated hours including 
preparatory work, survey development, data analysis, documentation, results review, and 
presentation. Cost of mailings, follow-up contact, office supplies, and software packages/online 
tools were the greatest monetary expense and were an in-kind donation.  APRN participation 
time completing the pre-/ post-surveys and the QI activity was estimated at 25 minutes.  Non-
monetary benefits included improved patient care via best practice behaviors with the goal of 
reduced morbidity and mortality.  See Appendix H for cost/benefit analysis/budget. 
Strengths 
A number of strengths and successes were associated with the DNP project.  Potential 
facilitators for the project included the national opioid crisis and its associated publicity, as well 
as Arizona’s well-developed PMDP.   This project focused exclusively on APRN practice.  It 
highlighted APRN practice modification in accordance with best practice recommendations.  
Results revealed improvement in AZCSPMP utilization across all best practice behaviors.  An 
unexpected finding was the markedly increased compliance with the Arizona mandate of PDMP 
registration was reported by 100% of respondents. Outcomes supported previous findings that 
providers utilize subjective impression as the indicator for CSPMP review and were significantly 
correlated with best practice behaviors. Lastly, the data collected contained a number of factors 
related to PDMP utilization and barriers and is amenable to further analyses.    
Limitations 
  Despite the noted successes and strengths of the project, there were some limitations, 
including those related to project design.  Response rate was low, limiting generalizability of 
findings.  The low response rate was not entirely surprising based upon the original means of 
contact by U.S. Postal Service.  The goal sample size of 161 was not met, thus the standard 
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confidence interval of .80 and a margin of error of 0.05 was not achieved.  A repeated measures 
design could be utilized in the future to test for significant differences pre- and post-intervention.  
Study findings and limitations lay the groundwork for future QI initiatives.  Future projects can 
build upon this project’s findings and limitations. 
Dissemination 
The DNP student presented outcomes and recommendations to several stakeholders.  
This included the clinical site, the Arizona Board of Nursing, and Dr. John A. Pugliese, the 
original survey developer.  The DNP student submitted the doctoral Capstone project to 
Scholarworks for publication. The DNP student may also pursue additional dissemination 
opportunities by presenting at applicable conferences and/or submitting the project summary to 
appropriate journals for publication. This best practice review can direct future QI efforts.  
Follow-up QI initiatives/projects with APRNs in Arizona as well as other states could be 
conducted to assess change over time. Post-project continuation will help ensure sustainability of 
change.   
Conclusion 
Best practices when prescribing opioids for chronic, non-cancer, non-terminal pain is 
critical for patient safety and positive outcomes. Opioid overdoses and opioid deaths are 
preventable.  Targeted interventions are necessary to minimize the morbidity and mortality of 
this epidemic.  The national publicity of the opioid crisis provides an opportunity to improve 
health care. This Capstone project utilized best practices for risk mitigation.  Evaluating opioid 
prescribing practices and PDMP utilization from a QI perspective opens the door for systematic 
change, which can improve the utility of PDMPs and ultimately improve patient safety and 
quality of life. 
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Appendix A 
 
Theoretical Framework 
Fishbein and Ajzen’s (2010) 
Theory of Reasoned Action and Planned Behavior 
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Appendix B 
Board of Nursing  Approval of Requested List for QI Project 
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Appendix B (continued) 
Board of Nursing  Approval of Requested List for QI Project 
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Appendix C 
Invitation to Participate in Project 
 
To my Capstone Project! 
I am enrolled in the onIine DNP program at the University of Massachusetts – Amherst.   
 
I am conducting an analysis related to opioid prescribing in Arizona & would be most grateful if you would 
be willing to participate.  
 
For more information, please contact me at bvigue@umass.edu or go to www.surveymonkey.com  . . . 
 
Best Regards,  
Brenda Vigue, APRN, MS, FNP-BC, PMHNP-BC 
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Appendix D 
Letter Requesting Permission to Use Survey 
 
July 19, 2018 
 
John A. Pugliese, PhD 
1616 Capitol Avenue 
Suite 74.436, Building 174 
Sacramento, CA  95814 
 
Dear Dr Pugliese: 
I am a doctoral student enrolled in the Doctorate in Nursing (DNP) program at the University of 
Massachusetts Amherst, under the direction of Dr. Terrie Black, DNP Project Chair.  Dr. Black can be 
reached at tblack@umass.edu.  My DNP Capstone Project is entitled, Mitigating Prescription Opioid 
Risk:  Prescription Drug Monitoring Programs,  
I would like your permission to use the Opioid Prescribing by Medical Toxicologists survey in 
my doctoral project.  I would like to use and print your survey under the following conditions: 
 I will use the surveys only for my DNP scholarly project and will not sell or use it with any 
compensated or curriculum development activities. 
 I will include the copyright statement on all copies of the instrument. 
 I will send a copy of my completed DNP scholarly project to your attention upon completion of 
the study. 
If these are acceptable terms and conditions and/or there are any other considerations you would 
like, please contact me by email at bvigue@umass.edu.  Thank you.   
Sincerely, 
 
Brenda Vigue, APRN, MS, FNP-BC, PMHNP-BC 
College of Nursing 
University of Massachusetts Amherst 
Skinner Hall 
651 North Pleasant Street 
Amherst, MA 01003-9299 
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Appendix E 
Email Granting Permission to Use Survey 
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Appendix F 
Preliminary Survey 
I. Do you have prescribing privileges in the state of Arizona?  Yes, No—Inclusion question 
II. Do you possess an active DEA certificate for the state of Arizona?  Yes, No—Inclusion question 
III. Concerned about misuse of control substances: not concerned at all (0) to a great deal (2). 
a. How concerned are you about prescription drug misuse and abuse among patients in Arizona? 
b. How concerned are you about prescription drug misuse and abuse among patients in the 
community where you practice? 
IV. Usefulness of the PDMP: not useful at all (0) to very useful (3). 
a. How useful to you is the Arizona Controlled Substances Prescription Monitoring Program 
(CSPMP) for helping manage patients with pain?  
b. How useful to you is the CSPMP for helping build trust with patients?  
c. How useful to you is the CSPMP for informing decisions to prescribe/dispense controlled 
substances?  
d. How useful to you is the CSPMP for identifying patients filling prescriptions from multiple 
doctors and/or pharmacies?  
e. How useful to you is the CSPMP for identifying patients who misuse or abuse controlled 
prescription drugs?  
V.  PDMP normative believes: 11-point scale, 0% to 100%  
a. What percentage of your colleagues do you think uses the CSPMP at least weekly?  
b. What percentage of your colleagues do you feel ought to be using the CSPMP at least weekly?  
VI. Professional and moral obligation: Strongly disagree (1) to strongly agree (5) 
a.  I have a professional responsibility to check the CSPMP when prescribing/dispensing controlled 
substances.  
b. Checking the CSPMP when prescribing/dispensing controlled substances is the right thing to do.  
c. Using the CSPMP when prescribing/dispensing controlled substances is considered standard of 
care.  
d. Prescribing/dispensing controlled substances without checking the CSPMP would be morally 
wrong.  
e. Checking the CSPMP when prescribing/dispensing controlled substances is not a necessary part of 
my job.  
VII. Barriers to use: Strongly disagree (1) to strongly agree (5).  
a. The CSPMP is helpful.  
b. The CSPMP is not relevant to my practice.  
c. The CSPMP is easy to use.  
d. I don’t know how to use the CSPMP.  
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Appendix F (continued) 
Survey 
a. I have limited or no access to the CSPMP while I practice.  
b. The CSPMP is checked by someone else in the office. Never (0) to always (4). 
VIII. How long have you been using the CSPMP?:  Less than three months (1) to more than one year (4).  
IX. How likely are you to use the CSPMP at least once in the next three months? Extremely unlikely (1) to 
extremely likely (4).   
X. Gender (M, F) 
XI. Age (7 categories)  
XII. Years in practice (In years) 
XIII. Race/ethnicity  
a. White 
b. Black 
c. American/Alaskan Native 
d. Asian 
e. Native Hawaiian/Pacific Islander 
f. Other 
XIV. Hispanic or Latino (Yes, No) 
XV. Specialty 
a. Family practice 
b. Specialty clinic 
c. Women’s health 
d. Behavioral health/psychiatry 
e. Midwifery/OBGYN 
f. Pediatrics 
g. Other 
XVI.  Normative beliefs/best practice (Not from original survey): Less than once/month (1) to every day (6) 
a. I check an initial 12-month PDMP report prior to prescribing opioids for patients with chronic 
non-cancer, non-terminal pain. 
b. I review the MME of prior prescriptions. 
XVII. Normative beliefs/best practices—(Not from original survey):  Never (1) to always (5)   
c. I check the CSPMP every three months or sooner for patients receiving opiates for chronic non-
cancer, non-terminal pain.  
d. I document concerning PDMP review results. 
e. I maintain an opioid dosage < 50 morphine milligram equivalents (MMEs) per day. 
 
 
Note.  Reprinted from Pugliese, J. A., Wintemute, G. J., & Henry, G. S.  (2018).  Psychosocial correlates of clinicians’ prescription drug 
monitoring utilization.  American Journal of Preventative Medicine, 31, 556. doi: 10.1016/j.amepre.2018.02.009. 
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Appendix G 
Post-intervention Survey 
I. Concerned about misuse of control substances: not concerned at all (0) to a great deal (2). 
a. How concerned are you about prescription drug misuse and abuse among patients in Arizona? 
b. How concerned are you about prescription drug misuse and abuse among patients in the 
community where you practice? 
II. Usefulness of the PDMP: not useful at all (0) to very useful (3). 
a. How useful to you is the Arizona Controlled Substances Prescription Monitoring Program 
(CSPMP) for helping manage patients with pain?  
b. How useful to you is the CSPMP for helping build trust with patients?  
c. How useful to you is the CSPMP for informing decisions to prescribe/dispense controlled 
substances?  
d. How useful to you is the CSPMP for identifying patients filling prescriptions from multiple 
doctors and/or pharmacies?  
e. How useful to you is the CSPMP for identifying patients who misuse or abuse controlled 
prescription drugs?  
III.  PDMP normative believes: 11-point scale, 0% to 100%  
a. What percentage of your colleagues do you think uses the CSPMP at least weekly?  
b. What percentage of your colleagues do you feel ought to be using the CSPMP at least weekly?  
IV. Professional and moral obligation: Strongly disagree (1) to strongly agree (5) 
a.  I have a professional responsibility to check the CSPMP when prescribing/dispensing controlled 
substances.  
b. Checking the CSPMP when prescribing/dispensing controlled substances is the right thing to do.  
c. Using the CSPMP when prescribing/dispensing controlled substances is considered standard of 
care.  
d. Prescribing/dispensing controlled substances without checking the CSPMP would be morally 
wrong.  
e. Checking the CSPMP when prescribing/dispensing controlled substances is not a necessary part of 
my job.  
V. Barriers to use: Strongly disagree (1) to strongly agree (5).  
a. The CSPMP is helpful.  
b. The CSPMP is not relevant to my practice.  
c. The CSPMP is easy to use.  
d. I don’t know how to use the CSPMP.  
c. I have limited or no access to the CSPMP while I practice.  
d. The CSPMP is checked by someone else in the office. Never (0) to always (4). 
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Appendix G (continued) 
Post-intervention Survey 
VI. How long have you been using the CSPMP?:  Less than three months (1) to more than one year (4).  
VII. How likely are you to use the CSPMP at least once in the next three months? Extremely unlikely (1) to 
extremely likely (4).   
VIII. Subjective impression—(Not from original survey):  Never (1) to always (5)   
a. I check a PDMP report only when I am concerned a patient is misusing their opioid medication. 
IX.  Normative beliefs/best practice (Not from original survey): Less than once/month (1) to every day (6) 
f. I check an initial 12-month PDMP report prior to prescribing opioids for patients with chronic 
non-cancer, non-terminal pain. 
g. I review the MME of prior prescriptions. 
X. Normative beliefs/best practices—(Not from original survey):  Never (1) to always (5)   
h. I check the CSPMP every three months or sooner for patients receiving opiates for chronic non-
cancer, non-terminal pain.  
i. I document concerning PDMP review results. 
j. I maintain an opioid dosage < 50 morphine milligram equivalents (MMEs) per day. 
 
 
Note.  Reprinted from Pugliese, J. A., Wintemute, G. J., & Henry, G. S.  (2018).  Psychosocial correlates of clinicians’ prescription drug 
monitoring utilization.  American Journal of Preventative Medicine, 31, 556. doi: 10.1016/j.amepre.2018.02.009. 
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Appendix H 
 
Cost/benefit Analysis 
  Cost Benefit 
Monetary 
 
Survey Monkey access $224.00  
Office supplies 
Toner cartridges  
Paper  
Misc.  
 
$241.95 
$67.34 
$41.07 
 
Professional editing $484.00  
Arizona Board of Nursing 
– APRN mailing list 
$100.00  
Postcards $150.00  
Mailing labels $40.00  
Postage $595.00  
SPSS statistical software $99.00  
MONETARY TOTAL $2,042.36  
Non-monetary APRNs 25 minutes Improved pt. care 
Project director – time 760 hours Improved pt. care 
Patients   Reduced morbidity & 
mortality 
   
 
 
 
 
 
